Equity Overview
Price & Market Data
Price: $0.33
Daily Change: -$0.0075 / 2.27%
Range: $0.33 - $0.34
Market Cap: $24,667,566
Volume: 25,934
Performance Metrics
1 Week: -5.79%
1 Month: 113.9%
3 Months: 83.14%
6 Months: -36.77%
1 Year: -76.27%
YTD: -47.50%
Company Details
Employees: 63
Sector: Finance
Industry: Financial conglomerates
Country: United States
Details
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.